Additional Information About Drug Price Negotiation and CBO’s Simulation Model of Drug Development
Report
In response to a request from Budget Committee Chairman Jodey Arrington and Congressman Michael C. Burgess, CBO provides information about its analysis of federal policies that affect the development of new drugs in the United States.
This letter provides additional information about the Congressional Budget Office’s analysis and simulation model related to federal policies that affect the development of new drugs in the United States. In particular, it provides information about CBO’s estimates of the budgetary effects of drug provisions in the 2022 reconciliation act, trends in venture capital investment in drug development, and CBO’s transparency efforts and planned future work in the area of drug development.
